Fremanezumab for Migraine

This trial investigates whether the migraine treatment fremanezumab can also improve sleep quality for migraine sufferers. Fremanezumab is already approved for preventing migraines, but researchers aim to determine if fewer migraines correlate with better sleep. The trial involves regular assessments of migraines and sleep over several months. It seeks participants aged 18 to 65 who began experiencing migraines before age 50, have 10 to 25 headache days per month, and frequently encounter sleep troubles. As a Phase 4 trial, this research aims to understand how this FDA-approved and effective treatment can benefit more patients.

The trial requires that you do not start or change the type, dosage, or frequency of any preventive medications for conditions other than migraine that might affect the study, such as antidepressants or beta-blockers. If you are currently on a migraine preventative therapy, you cannot participate in the trial.

Research has shown that fremanezumab is generally safe for people with migraines. In various studies, patients tolerated fremanezumab well. Long-term use not only reduced the number of migraine days but also caused few side effects. Most people did not experience serious negative reactions to the treatment.

Fremanezumab is unique because it targets a specific protein involved in migraine attacks called calcitonin gene-related peptide (CGRP). Unlike traditional migraine treatments that often focus on relieving symptoms after they start or use general pain relief methods, fremanezumab works by preventing migraines from occurring in the first place. This targeted approach means fewer headaches and improved quality of life for patients. Researchers are excited because fremanezumab offers a more precise way to manage migraines with potentially fewer side effects than existing treatments.

Research has shown that fremanezumab effectively prevents migraines. Studies found that over 66% of individuals with occasional migraines and 51.6% with frequent migraines experienced at least a 50% reduction in their monthly migraine days. Additional evidence confirms that fremanezumab decreases both the frequency and severity of migraines over time. This treatment targets a specific protein involved in migraine attacks, helping to prevent them before they start. These positive effects have consistently appeared in real-world use, demonstrating a strong track record for this medication.⁴⁶⁷⁸⁹